<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679740</url>
  </required_header>
  <id_info>
    <org_study_id>C1908</org_study_id>
    <nct_id>NCT04679740</nct_id>
  </id_info>
  <brief_title>Resorbable Magnesium Scaffolds Registry</brief_title>
  <official_title>RMS (Resorbable Magnesium Scaffolds) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry follows the ESC/EACTS guideline and further investigates the clinical&#xD;
      performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world&#xD;
      setting within the scope of its intended use without further (medical related) exclusion&#xD;
      criteria according to their respective instructions for use (IFU).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>According to ARC-2 definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>According to ARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death (CD)</measure>
    <time_frame>12 months</time_frame>
    <description>According to ARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel MI</measure>
    <time_frame>12 months</time_frame>
    <description>According to ARC-2 definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite scaffold thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>According to ARC-2 definition</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1106</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magmaris</intervention_name>
    <description>MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.</description>
    <other_name>Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic coronary artery disease needing the treatment of de novo native&#xD;
        coronary artery lesions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  According to the IFU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  According to the IFU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Galli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Calvin Bahr, M.Sc.</last_name>
    <phone>+41754427424</phone>
    <email>calvin.bahr@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Center Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Toelg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz-und Gefäßzentrum Oberallgäu-Kempten</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Torzewski, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Registry</keyword>
  <keyword>Magmaris</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>PCI</keyword>
  <keyword>Resorbable Magnesium Scaffolds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The primary outcome data will be shared after the publication of it.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

